News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|June 17, 2024

Treatment Option for Polycythemia Vera

Author(s)Sponsored Content

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemi: © stock.adobe.com.

FDA Grants Breakthrough Designation to INCA-33989 in Essential Thrombocythemia

December 15th 2025

Nuvisertib combination is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in R/R myelofibrosis.

Momelotinib Combo is Safe and Helps Ease Symptoms in Myelofibrosis

December 10th 2025

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

New Data Support Pelabresib Combination in Untreated Myelofibrosis

December 9th 2025

myelofibrosis

An Educational Overview of Newly Diagnosed Stage 1 Myelofibrosis

December 4th 2025

Image of woman.

What Fatigue Feels Like for a Patient With Polycythemia Vera

December 3rd 2025

Trending on CURE

Acupuncture Improves Cognitive Function in Breast Cancer Survivors

From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey

Light the Night and Survivorship: The Importance of Remembrance

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

© 2025 MJH Life Sciences^®

All rights reserved.